Leerink Partners Culture?

Currently a student at a semi-target looking to break into IB after graduation. Lots of family in the south east so would prefer to stay close to them (not as interested in NYC or other north east locations).

Very curious on Leerink Charlotte right now (healthcare interest, location, etc). Any insights into this group in particular? Interested but very cautious as I've heard horror stories of horrid culture / treatment of juniors by associates upward / sweatshop hours. Can anyone confirm? Thoughts on other offices too?

30 Comments
 

Going to give some measured feedback aside from the usual disgruntled emotion that usually gets tossed around on here as a former employee. 1st off I think we need to acknowledge that the biopharma side of this business is second to none - though I have mixed to negative feelings on the HC Services side. Charlotte office in particular primarily revolves around pharma services and CDMO but unfortunately has taken a step back (even pre-bk) with one of the top MDs running the show down there leaving for RayJ. This has only been crippled further by the support in NY also being poached by RayJ some time back and as of now I think is really a shell of it's former self.... Now with that being said I think the guys out in Charlotte are phenomenal guys and VERY different culturally to the NY crowd. 

Firm wide - without getting into the specs of it there were issues pre-bk but since then culture as mentioned by some on this forum has really taken a nose dive (I've literally had at least 3 former interns who matriculated FT call me for advice unsolicited b/c they literally have no idea wtf is happening and the place is unrecognizable, and make no mistake there is a real fear of repercussion to speak up about the issues and a lot of firing happening atm at all levels). I think all of us who got out in the last 6 months (whether forced or otherwise) are really happy we did when we did b/c it really began to reach an inflection point after the bk. MDs are phenomenal across the board but the issue lies in the VP / ASO crowd which has contributed to 1) a lack of development / reps across key quantitative skills, 2) political and snipey workplace, 3) lack of visibility on what this product will look like in a years time, & 4) Hunger games level factionalization within the analyst pool. For reference many of the heavy hitter SMD / MDs have already jumped ship for better ops (see new articles about Jed Brody if you need any proof) and those which are still around I'm pretty positive won't be if push comes to shove come contract renewal.

IMO - if you are serious about making IB a long-term career path I think there might be an argument to give it a look, but otherwise I'd say that the lack of job security (in excess of IB generally in a stagnant market), obvious cultural issues, and real uncertainty of the firm being able to come back from the brink would have me looking elsewhere if I were in your shoes. There are plenty phenomenal other HC coverage groups to look at and I just think you're better off looking for a place where at least you know you will attain the skills necessary for exit if that is what you choose sans the political BS that inevitably would come along with this one.

 

Yep, reply to this under your username and I’ll reach out. No problem setting some time to chat via phone if needed

 

Regarding top-down management styles, will agree with above poster that senior leadership at Leerink is top-notch. But, the example set by them doesn't always flow down through the hierarchy. 

 

I can speak for Leerink NY but i heard the culture is similar at all branches

Avoid at all costs.  Associates have openly admitted to “dumping work” on analysts just because they can. The higher ups are lazy and have never been hardworking at anything in their lives. You can tell everything’s been handed to them because they do not take accountability for any work. They also have severe communication issues within the firm. Tasks get created for absolutely no reason. And mid level management cannot even agree on comments given on tasks.

Lack of deal closing ability by senior team. Only a few people here know what they’re doing, and the rest create unnecessary work because of their incompetency and insecurity. analysts and associates have been flocking away making the workload for junior staff even more atrocious. AVOIDDDDDDDDDDDD

btw i don’t work there but my roommate does. he is a trooper for staying all this time honestly , no one at this firm makes it easy. And the stuff i’ve heard about the higher ups…………I’ve never heard of a more passive aggressive and manners- lacking group of people ever in my life. 

 
Most Helpful

Former NYC biopharma junior here – happy to give some color.

First, I can say with confidence that most of the really negative culture feedback you’ll hear is about the healthcare services team, which I’d be very cautious about applying to. In my view, healthcare services is by far the weakest team: they don’t do many actual deals, they’re constantly pitching, and a lot of senior people have left. Their founding group head, Barry Blake, who led their only truly notable deal the group has ever done (LHC / UnitedHealth in 2022), recently just left to become an MD at PWP, and several other seniors and juniors have moved on as well. A lot of the “tombstones” they show in decks are deals seniors did at prior banks since they've barely done any deals here. I personally wouldn’t be shocked if the team gets dramatically downsized or restructured over the next few years – it’s already shrunk from ~90 people at the peak to ~50 now. The whole group is based in NYC and is very big on facetime and you often see analysts in the office past midnight for the sole reason of not wanting to leave before their associates leave even if they have nothing else to do.

Biopharma is a very different story. Culturally and experience wise, it's significantly better, and as others have said in this thread, it’s the heart and soul of Leerink. On the equity side they consistently punch above their weight, leading a lot of big IPOs/follow-ons as lead-left with GS / MS / JPM off to the right. Historically it was mainly an equities platform with some M&A, but they recently built out a dedicated biopharma M&A team led by Tom Davidson (ex-head of PJT’s healthcare group), and they’ve already had strong results despite the buildout being relatively new. Pay is also top notch with essentially little to no buckets and making more than basically every other top bucket analyst at a EB and BB would make.

Culture on the biopharma side varies a lot by office:

  • NYC – Largest biopharma office. Culture is relatively chill for IB: most analysts are out by 7:00 pm. The team is big on bonding and people actually hang out outside of work.
  • Boston – Second-largest office (~20 people). From what I’ve heard, culture is the most formal of the bunch but analysts still get out of the office by like 8:00 pm. That said, it’s the most important office strategically since the group head sits there and a lot of the most marquee deals run out of Boston.
  • San Francisco – Third-largest office (~10ish people) but by far the most relaxed. From what i've heard most analysts are home by ~5:00 pm. SF covers a lot of West Coast companies, but because basically all the group's directors sit there, SF analysts often also work with NYC SMDs and the group head in Boston as well.
  • Charlotte – Smallest office but don't know too much about it, they kinda do their own thing focusing solely on spec pharma and also cover a little bit of healthcare services. From my understanding they mainly recruit kids from schools in the South (Vanderbilt / UNC) 

One thing to be aware of is that the healthcare services team currently has no female senior bankers (they previously had one, who left for Baird), and on the biopharma side there is only one female senior banker that sits in SF. I never had the chance to work with her directly, but I’ve heard she’s fantastic to work with. One other thing to note about Leerink is that it has quite a few nepo hires/interns – there are a number of kids of biopharma CEOs / investors / industry execs. Some of them are genuinely strong performers, others… less so, but that’s just the reality of the platform.

At the end of the day, if you're interested in healthcare and are thinking of applying to Leerink, definitely apply to the Biopharma team.

 

Any insight to which schools the other biopharma offices primarily recruit from other than the charlotte office recruiting from southern schools. 

 

The NY/BOS/SF biopharma offices generally recruit from a fairly tight list of ~10 target schools, but in practice three schools tend to dominate the intern classes across the three offices: Penn, Berkeley, and Georgetown. The NY office has seniors who strongly favor Penn and Berkeley, while SF has a few people who are particularly keen on Georgetown. That said, each of the three offices has at least one alumni from all three of those schools.

 

Very true on services. In my experience having worked on the team previously, most of the good juniors and seniors who had been there since the group’s founding in 2021 have already lateraled to greener pastures like MS, GS, and CVP. One of the most frustrating things for juniors on the services team is that exiting to PE/VC is very difficult, because you get very limited exposure to meaningful live deals that actually close (outside of some bogus hospital sales) and Leerink just isn’t a major player in the services space. As a result, most of the people who remain on the services team are those who aren’t good enough to lateral to another bank or find a buyside exit, which doesn’t exactly create the best environment for development or morale. 
It’s honestly quite a shame to see what’s happened with the team because back in 2021 when most of us had joined, the group had a ton of potential to be a major player in the space as they hired a lot of top seniors and the group had great morale. The former group head would often pay out of his own pocket for the healthcare services juniors to take a ski trip for the weekend, which were really fun. Completely agree with OP to avoid joining the services group if possible, but if you end up choosing the group I’d try and spend that summer networking with other places for FT recruiting.

 
[Comment removed by mod team]
 

Hi! This is the most helpful comment I've read by far. I do wish I had seen this before, given that I have my Superday for the HCS team this week. A little context -- I'm a female coming from a target school who's recruiting for SA and have my Superday with two Senior MDs, one of which I believe leads the medtech team. Both are male obviously, and the aforementioned one went to Berkeley. Any idea of what I can expect for them? Or insights on what techs/behaviorals I should prep for? Thanks in advance for your help.

 

Iure dolores odit nemo commodi sunt cum. Similique eius unde omnis aut delectus commodi iste. Necessitatibus sed earum omnis sunt nobis est. Consectetur reiciendis et voluptas enim labore asperiores. Omnis eum iure doloremque vitae. Sequi quo eos voluptatem odit. Esse quia debitis non est sunt sit cupiditate sed. Animi porro ab et voluptatem minima iure reiciendis.

Temporibus et rerum earum autem eveniet qui placeat aut. Molestiae sunt dolorum dignissimos et dolores vitae. Voluptate omnis tenetur ut saepe et corrupti ipsam.

A laudantium aut ea odit inventore sed veritatis. Tenetur vero incidunt unde quis aut excepturi. Dolores atque nihil laudantium repudiandae enim.

 

Et nihil delectus sapiente error et id itaque. Dolor quod non voluptatum est dolore aperiam. Quia est ut provident repellat error voluptate. Iusto autem doloribus consequuntur aut dolor. Vero aut autem consequatur tempora aperiam dolor similique. Excepturi ab iure aut at repellendus.

[Comment removed by mod team]

Career Advancement Opportunities

May 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.8%
  • JPMorgan 01 98.2%
  • Guggenheim Partners 01 97.6%
  • Morgan Stanley 07 97.1%

Overall Employee Satisfaction

May 2026 Investment Banking

  • Moelis & Company No 99.4%
  • Morgan Stanley 01 98.8%
  • Evercore 01 98.2%
  • BMO Capital Markets 12 97.6%
  • Banco Santander 01 97.0%

Professional Growth Opportunities

May 2026 Investment Banking

  • Moelis & Company No 99.4%
  • Evercore No 98.8%
  • Morgan Stanley 05 98.2%
  • JPMorgan No 97.6%
  • BMO Capital Markets 12 97.1%

Total Avg Compensation

May 2026 Investment Banking

  • Vice President (14) $434
  • Associates (43) $259
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (22) $179
  • Intern/Summer Associate (13) $156
  • 1st Year Analyst (75) $151
  • Intern/Summer Analyst (65) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
kanon's picture
kanon
99.0
3
BankonBanking's picture
BankonBanking
99.0
4
Secyh62's picture
Secyh62
99.0
5
DrApeman's picture
DrApeman
98.9
6
Betsy Massar's picture
Betsy Massar
98.9
7
dosk17's picture
dosk17
98.9
8
CompBanker's picture
CompBanker
98.9
9
GameTheory's picture
GameTheory
98.9
10
bolo up's picture
bolo up
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”